ObvioHealth Announces Next Generation Virtual Research Platform and Ecosystem
Seamless integration of ObvioHealth patient-friendly app with digital device partners enables frictionless remote monitoring of patient vitals from home
NEW YORK, February 16, 2021 - ObvioHealth, a global Virtual Research Organization (VRO), announces its next generation platform offering enhanced remote patient monitoring capabilities for the company’s end-to-end decentralized clinical trial solutions.
ObvioHealth’s decentralized platform and smartphone app have been designed from inception with patients in mind. To date, dozens of ObvioHealth virtual trials have delivered best in class metrics for patient recruitment time, medication adherence and retention. The platform upgrade builds on this momentum, integrating an ecosystem of FDA-cleared devices to support remote monitoring through seamless connections to its patient-centric app.
Freshly-minted partnership agreements with BioIntelliSense, AliveCor and iHealth, allow healthcare providers and trial investigators to monitor up to 20 different clinical grade vital signs including heart rate, respiratory rate, temperature, blood pressure, oxygen saturation, ECG, coughing episodes, sweat, sleep, activity levels and body positioning – without patients ever having to step foot in a clinic. The data from the partner devices is transmitted back to ObvioHealth’s clinical trial platform, where it is centrally and continuously monitored, enabling immediate identification of adverse events and reducing time to response.
The new capabilities remove the last barrier to site-less trials for COVID-19 and other studies that previously required frequent patient touch points. “The flexibility of ObvioHealth’s decentralized solutions is accelerating the transition from site-centric clinical trials to virtual ones. Sponsors are reaping the benefits of an approach that is safer, more reliable, and more cost effective.” said Ivan Jarry, ObvioHealth’s CEO. “The need for site visits has long been a hindrance to efficient drug research; without them we can provide patients with a more comfortable experience and sponsors with richer, more continuous data.”